CO2024009021A2 - Inhibidores de raf quinasa y métodos de uso de los mismos - Google Patents

Inhibidores de raf quinasa y métodos de uso de los mismos

Info

Publication number
CO2024009021A2
CO2024009021A2 CONC2024/0009021A CO2024009021A CO2024009021A2 CO 2024009021 A2 CO2024009021 A2 CO 2024009021A2 CO 2024009021 A CO2024009021 A CO 2024009021A CO 2024009021 A2 CO2024009021 A2 CO 2024009021A2
Authority
CO
Colombia
Prior art keywords
methods
kinase inhibitors
raf kinase
raf
inhibitors
Prior art date
Application number
CONC2024/0009021A
Other languages
English (en)
Spanish (es)
Inventor
Daniel L Flynn
Yu Mi Ahn
Bourdonnec Bertrand Le
Lakshminarayana Vogeti
Original Assignee
Deciphera Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deciphera Pharmaceuticals Llc filed Critical Deciphera Pharmaceuticals Llc
Publication of CO2024009021A2 publication Critical patent/CO2024009021A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
    • C07D213/22—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing two or more pyridine rings directly linked together, e.g. bipyridyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CONC2024/0009021A 2021-12-09 2024-07-05 Inhibidores de raf quinasa y métodos de uso de los mismos CO2024009021A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163287873P 2021-12-09 2021-12-09
US202263393445P 2022-07-29 2022-07-29
PCT/US2022/081242 WO2023108108A1 (en) 2021-12-09 2022-12-09 Raf kinase inhibitors and methods of use thereof

Publications (1)

Publication Number Publication Date
CO2024009021A2 true CO2024009021A2 (es) 2024-08-08

Family

ID=84981511

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2024/0009021A CO2024009021A2 (es) 2021-12-09 2024-07-05 Inhibidores de raf quinasa y métodos de uso de los mismos

Country Status (14)

Country Link
US (2) US12319655B2 (cg-RX-API-DMAC7.html)
EP (1) EP4444429A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024546478A (cg-RX-API-DMAC7.html)
KR (1) KR20240133793A (cg-RX-API-DMAC7.html)
CN (1) CN119604491A (cg-RX-API-DMAC7.html)
AU (1) AU2022405116B2 (cg-RX-API-DMAC7.html)
CA (1) CA3240263A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024001691A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024009021A2 (cg-RX-API-DMAC7.html)
IL (1) IL313417A (cg-RX-API-DMAC7.html)
MX (1) MX2024007042A (cg-RX-API-DMAC7.html)
PE (1) PE20241934A1 (cg-RX-API-DMAC7.html)
TW (1) TW202337455A (cg-RX-API-DMAC7.html)
WO (1) WO2023108108A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102708177B1 (ko) 2018-01-31 2024-09-23 데시페라 파마슈티칼스, 엘엘씨. 위장관 기질 종양의 치료를 위한 병용 요법
US12083118B2 (en) 2018-03-29 2024-09-10 Arbutus Biopharma Corporation Substituted 1,1′-biphenyl compounds, analogues thereof, and methods using same
TW202430515A (zh) * 2022-09-28 2024-08-01 加拿大商愛彼特生物製藥公司 經取代之1-芳基胺基羰基-1’-雜芳基化合物、經取代之1-雜芳基胺基羰基-1’-雜芳基化合物及其使用方法
WO2024258917A1 (en) * 2023-06-13 2024-12-19 Deciphera Pharmaceuticals, Llc Dual raf and tubulin inhibitors and methods of use thereof
AU2024311847A1 (en) * 2023-06-13 2025-11-27 Deciphera Pharmaceuticals, Llc Dual raf and tubulin inhibitors and methods of use thereof
CN119101030A (zh) * 2023-09-08 2024-12-10 北京华益健康药物研究中心 用于治疗或预防冠状病毒感染的3cl蛋白酶抑制剂及其用途

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU759255B2 (en) 1998-01-29 2003-04-10 Amgen, Inc. PPAR-gamma modulators
US20080269265A1 (en) 1998-12-22 2008-10-30 Scott Miller Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas
DK1478358T3 (da) 2002-02-11 2013-10-07 Bayer Healthcare Llc Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese
TW200410945A (en) 2002-08-08 2004-07-01 Amgen Inc Vanilloid receptor ligands and their use in treatments"
DK2316831T3 (da) 2002-11-21 2013-06-10 Novartis Ag 2-(Morpholin-4-yl)pyrimidiner som phosphotidylinositol (PI)-3-kinaseinhibitorer samt deres anvendelse ved behandling af cancer
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
US7279576B2 (en) 2002-12-31 2007-10-09 Deciphera Pharmaceuticals, Llc Anti-cancer medicaments
US20050014753A1 (en) 2003-04-04 2005-01-20 Irm Llc Novel compounds and compositions as protein kinase inhibitors
US7504401B2 (en) 2003-08-29 2009-03-17 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
KR101195801B1 (ko) 2004-06-18 2012-11-05 밀레니엄 파머슈티컬스 인코퍼레이티드 Xa 인자 억제제
GB0415364D0 (en) 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
WO2006031852A1 (en) 2004-09-13 2006-03-23 Amgen Inc. Vanilloid receptor ligands and their use in treatments
ATE502025T1 (de) 2004-10-19 2011-04-15 Compass Pharmaceuticals Llc Arylcarboxamide und ihre verwendung als antitumormittel
CA2575764A1 (en) 2004-10-27 2006-05-11 Neurogen Corporation Diaryl ureas as cb1 antagonists
CA2592118C (en) 2004-12-23 2015-11-17 Deciphera Pharmaceuticals, Llc Urea derivatives as enzyme modulators
PL1836169T3 (pl) 2004-12-28 2012-07-31 Kinex Pharmaceuticals Llc Kompozycje i sposoby leczenia zaburzeń związanych z proliferacją komórek
US20060178388A1 (en) 2005-02-04 2006-08-10 Wrobleski Stephen T Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
EP1871762A2 (en) 2005-04-18 2008-01-02 Neurogen Corporation Subtituted heteroaryl cb1 antagonists
US8188113B2 (en) 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
US7897762B2 (en) 2006-09-14 2011-03-01 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of proliferative diseases
US7790756B2 (en) 2006-10-11 2010-09-07 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
GB0625659D0 (en) 2006-12-21 2007-01-31 Cancer Rec Tech Ltd Therapeutic compounds and their use
WO2008140895A1 (en) 2007-04-20 2008-11-20 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
US8343966B2 (en) 2008-01-11 2013-01-01 Novartis Ag Organic compounds
BRPI0915105A2 (pt) 2008-06-13 2019-09-24 Novartis Ag composto de 2,4'-biripidinila como inibidores da proteína cinase d úteis para o tratamento de ia insuficiência cardíaca e cancer
CA2742007C (en) 2008-10-29 2014-07-08 Deciphera Pharmaceuticals, Llc Cyclopropane amides and analogs exhibiting anti-cancer and anti-proliferative activities
EP2542536B1 (en) 2010-03-04 2015-01-21 Cellzome Limited Morpholino substituted urea derivatives as mtor inhibitors
BR112012027743A2 (pt) 2010-04-29 2017-03-14 Deciphera Pharmaceuticals Llc ciclopropil dicarboxamidas e análogos exibindo atividades anticâncer e antiproliferativas
EP2563773A1 (en) 2010-04-29 2013-03-06 Deciphera Pharmaceuticals, LLC Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activites
HK1202450A1 (zh) 2011-11-22 2015-10-02 Deciphera Pharmaceuticals, Llc. 表現出抗癌和抗增殖活性的吡啶酮酰胺以及類似物
AR090151A1 (es) 2012-03-07 2014-10-22 Lilly Co Eli Compuestos inhibidores de raf
US9187474B2 (en) 2012-03-07 2015-11-17 Deciphera Pharmaceuticals, Llc Raf inhibitor compounds
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
US9242969B2 (en) * 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
US9193719B2 (en) 2013-03-15 2015-11-24 Deciphera Pharmaceuticals, Llc 1,2,4-triazol-5-ones and analogs exhibiting anti-cancer and anti-proliferative activities
US9133183B2 (en) 2013-03-15 2015-09-15 Deciphera Pharmaceuticals, Llc Imidazolidinones and analogs exhibiting anti-cancer and anti-proliferative activities
US9012635B2 (en) 2013-03-15 2015-04-21 Deciphera Pharmaceuticals, Llc Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities
CN105120864B (zh) 2013-03-15 2017-05-17 德西费拉制药有限责任公司 表现出抗癌活性和抗增殖活性的2‑氨基嘧啶‑6‑酮及类似物
BR112015022263B1 (pt) 2013-03-15 2023-01-03 Deciphera Pharmaceuticals Llc N-acil-n-(piridin-2-il) uréias e análogos apresentando atividades anticâncer e antiproliferativas, seus usos, e composição farmacêutica
WO2014145029A2 (en) 2013-03-15 2014-09-18 Deciphera Pharmaceuticals, Llc N-acyl-n'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities
EA029981B1 (ru) 2013-08-27 2018-06-29 Бристол-Майерс Сквибб Компани Ингибиторы ido
US10329270B2 (en) 2013-10-21 2019-06-25 Merck Patent Gmbh Heteroaryl compounds as BTK inhibitors and uses thereof
WO2015059618A1 (en) 2013-10-22 2015-04-30 Glenmark Pharmaceuticals S.A. SUBSTITUTED PYRIMIDINE COMPOUNDS AS mPGES-1 INHIBITORS
US9457019B2 (en) 2013-11-07 2016-10-04 Deciphera Pharmaceuticals, Llc Methods for inhibiting tie-2 kinase useful in the treatment of cancer
US10266515B2 (en) 2013-12-30 2019-04-23 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
TN2016000270A1 (en) 2014-01-14 2017-10-06 Millennium Pharm Inc Heteroaryls and uses thereof.
JP6636014B2 (ja) 2014-09-12 2020-01-29 ノバルティス アーゲー Rafキナーゼ阻害剤としての化合物および組成物
WO2018104307A1 (en) 2016-12-09 2018-06-14 Bayer Pharma Aktiengesellschaft Aromatic sulfonamide derivatives and their use as anatagon i sts or negative allosteric modulators of p2x4
BR112019025346A2 (pt) 2017-05-30 2020-06-30 Deciphera Pharmaceuticals, Inc. uso de 1-[4-bromo-5-[1-etil-7-(metilamino)-2-oxo-1,2-dihidro-1,6-naftiridin-3-il]-2-fluorofenil]-3-fenilureia e análogos para o tratamento de cânceres associados a anormalidades genéticas no receptor alfa do fator de crescimento derivado de plaquetas
TW201940165A (zh) 2018-01-29 2019-10-16 美商卡普勒斯療法有限責任公司 包含6員中心環的srebp抑制劑
KR102708177B1 (ko) 2018-01-31 2024-09-23 데시페라 파마슈티칼스, 엘엘씨. 위장관 기질 종양의 치료를 위한 병용 요법
CN118903436A (zh) 2018-01-31 2024-11-08 德西费拉制药有限责任公司 治疗肥大细胞增多症的组合疗法
CN112189012B (zh) 2018-04-10 2024-02-13 神经孔疗法股份有限公司 作为pi3激酶和自噬途径的调节剂的三取代芳基和杂芳基衍生物
US11945803B2 (en) 2018-08-07 2024-04-02 Tosk, Inc. Modulators of RAS GTPase
SMT202500389T1 (it) 2018-12-28 2025-11-10 Deciphera Pharmaceuticals Llc Inibitori di csf1r per l'uso nel trattamento di tumori tenosinoviali a cellule giganti
JP2022525885A (ja) 2019-03-22 2022-05-20 キネート バイオファーマ インク. Rafキナーゼの阻害剤
HUE065486T2 (hu) 2019-05-10 2024-05-28 Deciphera Pharmaceuticals Llc Fenilaminopirimidinamid autophágia inhibitorok és azok felhasználási eljárásai
HRP20231310T1 (hr) 2019-05-10 2024-02-02 Deciphera Pharmaceuticals, Llc Heteroarilaminopirimidin amidni inhibitori autofagije i postupci njihove primjene
EP4563150A3 (en) * 2019-05-13 2025-07-23 Novartis AG New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl) isonicotinamide as raf inhibitors for the treatment of cancer
BR112021022659A2 (pt) 2019-05-15 2022-03-29 Chemocentryx Inc Compostos triarílicos para o tratamento de doenças pd-l1
ES3072710T3 (en) 2019-06-17 2026-07-03 Deciphera Pharmaceuticals Llc Aminopyrimidine amide autophagy inhibitors and methods of use thereof
HRP20260411T1 (hr) 2019-08-12 2026-05-08 Deciphera Pharmaceuticals, Llc Ripretinib za liječenje gastrointestinalnih stromalnih tumora
US12691108B2 (en) 2019-08-12 2026-07-28 Deciphera Pharmaceuticals, Llc Methods for treating vascular malformations
AU2020371727B2 (en) 2019-10-24 2026-01-22 Pierre Fabre Medicament Inhibitors of RAF kinases
US20230046018A1 (en) 2019-12-06 2023-02-16 Medshine Discovery Inc. Biaryl compound as pan-raf kinase inhibitor
FI4084779T3 (fi) 2019-12-30 2024-12-16 Deciphera Pharmaceuticals Llc 1-(4-bromi-5-(1-etyyli-7-(metyyliamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yyli)-2-fluorifenyyli)-3-fenyyliurean koostumuksia
BR112022015109A2 (pt) 2020-01-29 2022-11-08 Foghorn Therapeutics Inc Compostos e usos dos mesmos
CN115175902B (zh) 2020-03-13 2024-07-26 郑州同源康医药有限公司 一类用作激酶抑制剂的化合物及其应用
WO2022060996A1 (en) * 2020-09-18 2022-03-24 Kinnate Biopharma Inc. Inhibitors of raf kinases
TW202229239A (zh) 2020-09-23 2022-08-01 日商武田藥品工業股份有限公司 作為ripk2抑制劑之3-(6-胺基吡啶-3-基)苯甲醯胺衍生物
US11377431B2 (en) 2020-10-12 2022-07-05 Kinnate Biopharma Inc. Inhibitors of RAF kinases
JP2023550638A (ja) 2020-11-25 2023-12-04 デシフェラ・ファーマシューティカルズ,エルエルシー ウイルス感染症の処置に使用するための、vsp34阻害剤としてのモルホリノ誘導体
WO2022115546A1 (en) 2020-11-25 2022-06-02 Deciphera Pharmaceuticals, Llc Anti-viral activity of vps34 inhibitors
WO2022115558A1 (en) 2020-11-25 2022-06-02 Deciphera Pharmaceuticals, Llc Morpholino derivatives as vsp34 inhibitors for use in the treatment of a viral infection
EP4251156A1 (en) 2020-11-25 2023-10-04 Deciphera Pharmaceuticals, LLC Anti-viral activity of vps34 inhibitors
CN117083064A (zh) 2020-11-25 2023-11-17 德西费拉制药有限责任公司 作为vps34抑制剂用于治疗病毒感染的吡啶基吡啶酮衍生物
WO2022115549A1 (en) 2020-11-25 2022-06-02 Deciphera Pharmaceuticals, Llc Anti-viral activity of vps34 inhibitors

Also Published As

Publication number Publication date
CA3240263A1 (en) 2023-06-15
AU2022405116B2 (en) 2026-06-11
WO2023108108A1 (en) 2023-06-15
IL313417A (en) 2024-08-01
CN119604491A (zh) 2025-03-11
US20230257352A1 (en) 2023-08-17
JP2024546478A (ja) 2024-12-24
US20250250235A1 (en) 2025-08-07
US12319655B2 (en) 2025-06-03
KR20240133793A (ko) 2024-09-04
AU2022405116A1 (en) 2024-07-11
TW202337455A (zh) 2023-10-01
MX2024007042A (es) 2024-09-04
CL2024001691A1 (es) 2024-11-15
EP4444429A1 (en) 2024-10-16
PE20241934A1 (es) 2024-09-24

Similar Documents

Publication Publication Date Title
CL2024001691A1 (es) Inhibidores de raf quinasa y métodos de uso de los mismos
CO2021016768A2 (es) Inhibidores de la autofagia de heteroarilaminopirimidina amida y métodos de uso de estos
CO2021016765A2 (es) Inhibidores de la autofagia de heteroarilaminopirimidina amida y métodos de uso de estos
CO2022000260A2 (es) Inhibidores de la autofagia de la amida aminopirimidina y sus métodos de uso
CO2020013599A2 (es) Piridazinonas como inhibidoras de parp7
CL2022000922A1 (es) Aminas bicíclicas como inhibidores de la cdk2.
ECSP22011692A (es) Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2
ECSP15042895A (es) Compuestos de biaril-amida como inhibidores de cinasa
MX2020012261A (es) Inhibidores de kras g12c que comprenden un anillo de piperazina y uso de estos en el tratamiento del cancer.
CL2019000941A1 (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret.
CL2019002734A1 (es) Isoquinolinas como inhibidores de hpk1.
CL2019003394A1 (es) Inhibidores de kras g12c y métodos para su uso.
CO2020016619A2 (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso
CO2021001912A2 (es) Composiciones anti-cd112r y métodos
CL2019000511A1 (es) Inhibidores de procesos metabólicos celulares.
CL2021001027A1 (es) Inhibidores selectivos de rgmc y el uso de los mismos
NI201900049A (es) Inhibidores de la magl
CO2019000386A2 (es) Compuestos heterocíclicos como inmunomoduladores
CO2020001107A2 (es) Moduladores terapéuticos del modo inverso de la atp sintasa
MX2018013663A (es) Metodos para tratar trastornos de sueño de ritmo circadiano.
UY35625A (es) Compuestos de tetrahidrocarbazol y carbazol carboxamida sustituidos como inhibidores de quinasa
CO2024008965A2 (es) Inhibidores de kit quinasa y métodos de uso de los mismos
CL2023001637A1 (es) Inhibidores de la vía jak1 para el tratamiento del vitíligo.
CO2021014351A2 (es) Derivados de quinolina y su uso para el tratamiento del cáncer